Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia.
2-arachidonoylglycerol (2-AG)
AM251
MAM model
cannabinoid CB1 receptor
endocannabinoid system
schizophrenia
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
received:
30
09
2021
revised:
19
12
2021
accepted:
21
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
1
4
2022
Statut:
epublish
Résumé
In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of Sprague-Dawley rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produces long-lasting behavioral alterations such as social withdrawal and cognitive impairment in adulthood, mimicking a schizophrenia-like phenotype. These abnormalities were preceded at neonatal age both by the delayed appearance of neonatal reflexes, an index of impaired brain maturation, and by higher 2-arachidonoylglycerol (2-AG) brain levels. Schizophrenia-like deficits were reversed by early treatment [from postnatal day (PND) 2 to PND 8] with the CB1 antagonist/inverse agonist AM251 (0.5 mg/kg/day). By contrast, early CB1 blockade affected the behavioral performance of control rats which was paralleled by enhanced 2-AG content in the prefrontal cortex (PFC). These results suggest that prenatal MAM insult leads to premorbid anomalies at neonatal age via altered tone of the endocannabinoid system, which may be considered as an early marker preceding the development of schizophrenia-like alterations in adulthood.
Identifiants
pubmed: 35053256
pii: biom12010108
doi: 10.3390/biom12010108
pmc: PMC8773886
pii:
doi:
Substances chimiques
Receptor, Cannabinoid, CB1
0
Methylazoxymethanol Acetate
592-62-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110165
pubmed: 33152383
Nat Chem Biol. 2012 Dec;8(12):999-1007
pubmed: 23103940
Schizophr Res. 2017 Oct;188:132-140
pubmed: 28108228
Front Behav Neurosci. 2011 Sep 28;5:64
pubmed: 21991251
Pharmacol Ther. 2009 May;122(2):150-202
pubmed: 19269307
J Neurochem. 2017 Nov;143(3):320-333
pubmed: 28628228
Biomedicines. 2021 Sep 04;9(9):
pubmed: 34572345
Neuropsychopharmacology. 2013 Jan;38(2):328-40
pubmed: 22968815
Br J Pharmacol. 2003 Feb;138(4):544-53
pubmed: 12598408
Nat Commun. 2012;3:1031
pubmed: 22929788
Schizophr Res. 2011 Aug;130(1-3):222-7
pubmed: 21624823
Front Psychiatry. 2015 Jul 06;6:91
pubmed: 26217239
Dev Neurobiol. 2008 Sep 15;68(11):1334-47
pubmed: 18666205
World J Biol Psychiatry. 2017 Mar;18(2):129-142
pubmed: 27223864
Anim Behav. 1965 Apr-Jul;13(2):234-41
pubmed: 5835840
Front Neurosci. 2018 Oct 23;12:703
pubmed: 30405327
J Nutr. 2007 Jan;137(1):118-24
pubmed: 17182811
Cell Tissue Res. 2013 Oct;354(1):309-30
pubmed: 23942897
Sci Rep. 2019 Apr 15;9(1):6062
pubmed: 30988364
Pharmacol Res. 2017 Jan;115:200-208
pubmed: 27884725
Eur J Pharmacol. 1998 Jan 2;341(1):39-44
pubmed: 9489854
Eur J Neurosci. 2014 Jul;40(1):2293-8
pubmed: 24698342
Behav Brain Res. 2009 Dec 7;204(2):306-12
pubmed: 19716984
Br J Pharmacol. 2012 Dec;167(8):1652-64
pubmed: 22762735
Eur J Pharmacol. 2018 Sep 5;834:230-239
pubmed: 30036537
J Cell Biol. 2003 Nov 10;163(3):463-8
pubmed: 14610053
Trends Pharmacol Sci. 2007 Feb;28(2):83-92
pubmed: 17222464
J Psychopharmacol. 2012 Jan;26(1):164-76
pubmed: 21669929
Prog Lipid Res. 2016 Apr;62:107-28
pubmed: 26965148
Pharmacol Res. 2021 Dec;174:105938
pubmed: 34655773
Cannabis Cannabinoid Res. 2021 Oct;6(5):381-388
pubmed: 34619043
Front Pharmacol. 2021 Feb 04;11:635763
pubmed: 33613289
Toxicol Appl Pharmacol. 2020 Nov 1;406:115214
pubmed: 32866524
Curr Top Behav Neurosci. 2010;4:391-433
pubmed: 21312408
J Psychiatr Res. 2017 Jul;90:46-59
pubmed: 28222356
Neuropsychopharmacology. 2013 Aug;38(9):1816-24
pubmed: 23563893
Cereb Cortex. 2005 Dec;15(12):2013-20
pubmed: 15788701
Mol Psychiatry. 2014 Jan;19(1):20-9
pubmed: 24166406
Neuropsychopharmacology. 2012 Mar;37(4):1057-66
pubmed: 22129780
Physiol Behav. 1971 May;6(5):573-6
pubmed: 5149448
Cell Tissue Res. 2015 Jan;359(1):279-94
pubmed: 25227552
Schizophr Bull. 2009 Mar;35(2):425-36
pubmed: 18990714
Br J Pharmacol. 2008 Mar;153 Suppl 1:S465-70
pubmed: 18311160
Pharmacol Res. 2021 Feb;164:105357
pubmed: 33285233
Neuropsychopharmacology. 2012 Jan;37(2):364-77
pubmed: 21956444
Mol Psychiatry. 2012 Dec;17(12):1228-38
pubmed: 22488257
Front Pharmacol. 2019 Mar 20;10:207
pubmed: 30949045
Prog Neurobiol. 2001 Dec;65(5):427-51
pubmed: 11689280
Eur J Pharmacol. 2012 May 15;683(1-3):148-54
pubmed: 22426162
Brain Res. 2018 Feb 15;1681:75-84
pubmed: 29274882
Br J Pharmacol. 2019 Nov;176(21):4087-4089
pubmed: 31769019
Int J Neuropsychopharmacol. 2010 Apr;13(3):373-86
pubmed: 19607756
Biomolecules. 2020 Jun 04;10(6):
pubmed: 32512776
Geroscience. 2021 Nov 24;:
pubmed: 34820764
Recent Pat CNS Drug Discov. 2014 Apr;9(1):13-25
pubmed: 24605939
Biochem Pharmacol. 2020 Jul;177:114004
pubmed: 32360362
Pharmacol Res. 2007 Nov;56(5):382-92
pubmed: 17950616
Schizophr Bull. 2012 May;38(3):444-56
pubmed: 20805287
J Cell Physiol. 2018 Jan;233(1):530-548
pubmed: 28300292
Dev Psychopathol. 2000 Summer;12(3):501-27
pubmed: 11014750
Toxicology. 2006 Jun 15;223(3):227-34
pubmed: 16698163
Neuropharmacology. 2019 Jan;144:193-207
pubmed: 30366002
J Psychiatr Res. 2011 Mar;45(3):354-60
pubmed: 20655545
Hum Psychopharmacol. 2013 Nov;28(6):586-93
pubmed: 24519692
J Vis Exp. 2017 Apr 24;(122):
pubmed: 28518104
Neuropharmacology. 2019 Mar 1;146:212-221
pubmed: 30496751
Front Behav Neurosci. 2011 Aug 17;5:49
pubmed: 21887137
Nord J Psychiatry. 2008;62(2):92-105
pubmed: 18569772
Physiol Behav. 1996 Sep;60(3):1013-8
pubmed: 8873284
J Neurosci. 2004 Jan 7;24(1):53-62
pubmed: 14715937
Neurobiol Dis. 2013 May;53:10-7
pubmed: 23220619
Neurotox Res. 2016 Nov;30(4):658-676
pubmed: 27577742
Eur J Pharmacol. 2001 May 11;419(2-3):207-14
pubmed: 11426843
Br J Pharmacol. 2010 Jun;160(3):544-8
pubmed: 20590564
Am J Med Genet. 2002 Dec 8;114(8):929-37
pubmed: 12457389
Eur J Neurosci. 1999 Dec;11(12):4213-25
pubmed: 10594647
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1205-10
pubmed: 19596038
FASEB J. 2021 Aug;35(8):e21793
pubmed: 34320234
NPJ Schizophr. 2016 Mar 09;2:16003
pubmed: 27336054
J Neurosci. 2006 May 24;26(21):5628-37
pubmed: 16723519
Dialogues Clin Neurosci. 2001 Dec;3(4):243-56
pubmed: 22033679
Eur Neuropsychopharmacol. 2001 Jun;11(3):209-13
pubmed: 11418280
Dev Psychobiol. 2017 Nov;59(7):807-821
pubmed: 28763098
Int J Neuropsychopharmacol. 2011 Feb;14(1):17-28
pubmed: 20196921